Imatinib and persistence of leukaemia stem cells
Added: Thursday 3 November 2011
A recent study shows that while imatinib mesylate (IM) treatment reduces the burden of leukaemia stem cells in chronic myelogenous leukaemia (CML) patients, there is selective retention of these cells. The results clearly showed that BCR-ABL+ stem cells persist in CML patients despite prolonged treatment with IM.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: